The Haifa, Israel-based company expects to publish results from the trial in November.
Meretzki is hopeful that results from the Phase II trial will be “good enough” to get marketing approval for the therapy from Israeli regulators without the need to conduct a Phase III trial. But he acknowledged that in the US, the Food and Drug Administration (FDA) will demand a late-stage trial.
Market Data 
Markets 
AI
